Table 2 Tau therapeutics in phase III (as of February 28, 2023)
From: The therapeutic landscape of tauopathies: challenges and prospects
Molecule Type | Company Name | Drug Name | Indication | Route of Administration | Mechanism of Action |
|---|---|---|---|---|---|
mAb | Eisai Co | E-2814 (anti-MTBR tau antibody; BAN 2401) | AD, dementia associated with AD | Intravenous | A humanized, high affinity, IgG1 antibody recognizing the tau MTBR. E2814 and its murine precursor, 7G6, as revealed by epitope mapping, are antibodies bi-epitopic for 4R and mono-epitopic for 3R tau isoforms because they bind to the sequence motif HVPGG. |
Small molecule | Annovis Bio | Buntanetap (ANVS-401; Posiphen) | AD, PD | Oral | Inhibits the production of neurotoxic proteins that are derived from APP and tau. It works by inhibiting ⍺-syn, tau and APP synthesis. |
BioVie Inc | NE-3107 (Triolex, HE3286) | AD | Oral | Inhibits extracellular signal-regulated kinase 1 and 2 (ERK 1 & 2). It inhibits the activity of major inflammatory mediators ERK, NFKappaB, and TNF. | |
TauRx Therapeutics | LMTX (hydromethylthionine mesylate, TRx 237, HMTM) | AD, MCI | Oral | Tau and TDP-43 protein aggregation inhibitor. |